Botanix Pharmaceuticals’ research on the antimicrobial potential of CBD has been supported by research data from a leading South American academic group.
Published in online journal BioRxiv, the new article supports Botanix’s discovery that synthetic CBD can also kill a select group of Gram-negative bacteria, including those responsible for the sexually transmitted disease gonorrhoea and challenging Clostridioides difficile (C.Diff) infections.
The new data was presented in the same week in which ABC’s Invisible Wars highlighted the global threat of antimicrobial resistance (AMR) and the specific challenges of Staph Aureus, Neisseria Gonorrhoea and C.Diff infections.
Top doctors and scientists from around the world spoke candidly about the threat posed by superbugs and AMR, which they compared to the impact of climate change and described as an “unfolding disaster”, getting worse every year.
Botanix is currently finalising plans for the next steps in its BTX 1801 antimicrobial program, including analysis of positive data from its Phase 2a clinical study in February 2021.
The double-blind, vehicle-controlled study was designed to evaluate the safety and local tolerability of two formulations of BTX 1801 to decolonise Staph and MRSA from the noses of healthy adults to reduce the risk of bacterial infections in surgical settings.
